Source: OncLive, June 2025
Douglas B. Johnson, MD, MSCI, a professor of medicine in the Division of Hematology/Oncology and leader of the Melanoma Clinical Research Program at Vanderbilt University Medical Center, outlined ongoing challenges and unmet needs in the immuno-oncology landscape for melanoma, despite advances in immune checkpoint inhibition.
Although many patients with metastatic melanoma achieve responses with frontline immunotherapy, approximately half derive limited or no benefit, underscoring the need for more effective primary and salvage treatment strategies, Johnson began.